A Chinese medicine composition for improving cognitive impairment in coronary heart disease and its application

Abstract

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for improving cognitive impairment in coronary heart disease and its use. The raw materials of the composition include the following components: Alpinia oxyphylla, Lycium barbarum, Fructus schizonepetae, Lotus seed core, Panax ginseng, Ligusticum chuanxiong, and Paeonia lactiflora. The composition of the present invention can improve cardiac function and structure after acute myocardial ischemia in coronary heart disease, reduce the area of ​​ischemic myocardial infarction, alleviate myocardial cell damage and myocardial fibrosis, alleviate damage to hippocampal neurons and ultrastructural changes, and improve learning and memory functions and cognitive behavioral performance.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving cognitive impairment in coronary heart disease and application thereof. Background Art

[0002] Both cardiovascular disease and cognitive impairment are major health hazards. Growing evidence indicates that cardiovascular health closely influences cognitive health, and the two are closely linked. The cardiovascular event chain, characterized by coronary atherosclerosis (from cardiovascular risk factors to end-stage heart disease such as heart failure), has expanded its impact beyond the heart, particularly to the brain, affecting cognitive function.

[0003] Cognitive impairment is the impairment of one or more cognitive functions that affects an individual's daily or social abilities. It ranges from mild cognitive impairment to dementia. Approximately 25% of dementia cases are attributable to cardiovascular risk factors and can be prevented by modifying these risk factors. Given the lack of treatments to modify dementia, effective prevention and management of cardiovascular disease are crucial for preventing cognitive impairment and slowing the transition from mild cognitive impairment to dementia.

[0004] Existing evidence suggests that the risk of cognitive impairment in patients with coronary heart disease can increase by up to 45%. This may be due to the worse vascular risk burden brought about by atherosclerotic disease, or it may be due to the direct consequences of cardiac dysfunction on the brain. The risk of dementia in patients with a history of myocardial infarction is 2-5 times that of those without such a history. This may be mainly attributed to chronic cerebral hypoperfusion caused by acute myocardial ischemia, which in turn induces inflammation, oxidative stress, immune response, blood-brain barrier damage, etc., leading to cognitive impairment, or due to myocardial fibrosis and contractile dysfunction, resulting in reduced cardiac output, or due to myocardial damage leading to the activation of systemic inflammation and neurohumoral factors, which directly impair cognitive function. However, the underlying biological mechanisms of cognitive impairment in coronary heart disease have not been fully elucidated, and there is currently no definite medication answer for the treatment of this disease.

[0005] Western medicine uses drugs to improve cognitive impairment, including cholinesterase inhibitors, ionotropic glutamate receptor antagonists, calcium ion antagonists, ginkgo biloba extract, nootropics, ergot alkaloid preparations, etc. However, as of now, there are no drugs for cognitive impairment in coronary heart disease.

[0006] Traditional Chinese Medicine (TCM) has long recognized the relationship between the heart and the brain, with sayings like "The heart is the sovereign organ, from which the spirit emerges," "The heart stores the pulses, and the pulses house the spirit," and "The heart and brain jointly govern the spirit." Based on its holistic approach, TCM proposes the concept of "heart-brain connectivity" and, based on the principle of "treating different diseases the same way," develops the concept of "treating the heart and brain together." This concept embodies the core principles of TCM's holistic approach and dialectical treatment, and incorporates modern medical understanding of the pathophysiology of cardiovascular and cerebrovascular diseases, grounded in clinical practice. Guided by this theory and adhering to Academician Chen Keji's theoretical insights on the treatment of coronary heart disease and cognitive dysfunction, a formula with remarkable efficacy for cognitive impairment in CHD has been developed through years of repeated clinical practice. This study has shown that it can improve cognitive impairment in rats following acute myocardial ischemia, providing experimental support for the clinical diagnosis and treatment of this disease. Summary of the Invention

[0007] In view of the deficiencies in the prior art, the present invention provides a Chinese medicine composition for improving cognitive impairment in coronary heart disease and its application.

[0008] In order to achieve the purpose of the present invention, the technical solutions adopted are as follows:

[0009] A traditional Chinese medicine composition for improving cognitive impairment caused by coronary heart disease. The raw materials of the composition include the following components: Alpinia oxyphylla, Lycium barbarum, Rhizoma divaricata, Lotus seed core, Ginseng, Ligusticum chuanxiong and Paeonia lactiflora.

[0010] The traditional Chinese medicine compound for treating cognitive impairment caused by coronary heart disease is composed of Alpinia oxyphylla, Lycium barbarum, Fructus schizonepetae, Lotus seed core, Ginseng, Ligusticum chuanxiong and Paeonia lactiflora.

[0011] Among them, Alpinia oxyphylla (Alpinia oxyphylla) kernel, the dried fruit of the ginger plant Alpinia oxyphylla, is known to tonify the kidneys, strengthen essence, reduce urination, warm the spleen, and stop diarrhea, improve complexion and prolong life, and enhance memory. Modern pharmacological research confirms that it contains a large number of compounds, including terpenes, flavonoids, and steroids, with antioxidant, anti-inflammatory, and cognitive-improving properties. Traditional Chinese Medicine (TCM) believes that the cognitive impairment associated with coronary heart disease is essentially a combination of underlying deficiency and superficial excess, with obstruction of the heart meridians throughout the disease. Deficiency of the five internal organs is the root cause, with kidney deficiency being the primary concern. As the Jingyue Complete Works states, "When the fundamentals are weakened, the person will inevitably become ill; when the fundamentals are damaged, the person will inevitably become endangered." When the kidneys are weakened, their ability to produce essence and blood stasis is impaired, leading to an imbalance between yin and yang. This generates turbid evil within the body, obstructing the brain's meridians and preventing it from awakening and replenishing the mind. Over time, this generates heat and wind, leading to mental dysfunction and cognitive abnormalities.

[0012] Lycium barbarum is neutral in nature and enters the liver and kidney meridians. "Compendium of Materia Medica" records that it has the effects of nourishing the liver and kidneys, improving intelligence and eyesight. It is often used to treat liver and kidney yin deficiency, dizziness and forgetfulness.

[0013] The herb, also known as the walnut cracker or walnut septum, is the septum of the walnut kernel. It's also found in the famous Qinggong Shoutao Pills (created during the reign of Emperor Kangxi) for tonifying the kidneys and preventing aging. It's bitter, astringent, and neutral in nature, entering the spleen and kidney meridians. Its primary benefits include diuresis, clearing heat, strengthening the spleen and kidneys, and astringing semen to stop nocturnal emission. It can also improve symptoms such as memory loss, soreness of the waist and knees, tinnitus, hearing loss, and frequent urination at night.

[0014] Lotus seed core is the middle green radicle of the mature seed of the lotus plant of the Nymphaeaceae family. It is a food and medicine product with both health care and medicinal value. "Compendium of Materia Medica" records that it has the effect of clearing the heart, relieving heat and eliminating restlessness.

[0015] Ginseng has a sweet and slightly bitter taste and a mild nature. It enters the spleen, lung, and heart meridians, tonifying qi, strengthening the body, promoting fluid production, calming the mind, and improving intelligence. It is commonly used to treat a variety of conditions, including cardiovascular and cerebrovascular diseases, chronic fatigue syndrome, diabetes, and neurodegenerative diseases. The Shennong Herbal Classic states that it can "tonify the five internal organs, calm the spirit, stabilize the soul, relieve palpitations, dispel evil spirits, brighten the eyes, improve mood, and enhance intelligence; long-term consumption can also lead to weight loss and longevity." Modern research has confirmed that ginseng's saponins are one of the main components of ginseng's therapeutic effects, including myocardial protection, regulating glucose and lipid metabolism, enhancing learning and memory, improving cognitive function, and protecting the nervous system.

[0016] Red peony root can promote blood circulation, disperse blood stasis and relieve pain. It is cool in nature. "Compendium of Materia Medica" calls it "the clearest and strongest fragrance, so it can ward off all evil spirits." When combined with Chuanxiong, which can enter the blood and promote qi circulation, resolve blood stasis and relieve stagnation, it has a suitable combination of cold and warm properties and its efficacy is doubled. It can dilate coronary arteries, protect vascular endothelial cells, resist platelet aggregation, and inhibit vascular remodeling.

[0017] Preferably, the raw materials of the composition include the following components by weight: 15-25 parts of Alpinia oxyphylla, 15-25 parts of wolfberry, 15-25 parts of Rhizoma Cibotii, 3-10 parts of lotus seed core, 5-15 parts of ginseng, 5-15 parts of Ligusticum chuanxiong, and 5-15 parts of red peony root.

[0018] Preferably, the raw materials of the composition include the following components by weight: 15-20 parts of Alpinia oxyphylla, 15-20 parts of wolfberry, 15-20 parts of Rhizoma Cibotii, 3-6 parts of lotus seed core, 10-15 parts of ginseng, 10-15 parts of Ligusticum chuanxiong, and 10-15 parts of red peony root.

[0019] Another object of the present invention is to provide a method for preparing the above composition, comprising:

[0020] Mix Alpinia oxyphylla, wolfberry, fenxinmu, lotus seed core, ginseng, Chuanxiong and red peony root, add water and boil.

[0021] Preferably, the decoction is performed 1-3 times, and the decoction time for each time is 0.5-1.5 hours.

[0022] Preferably, the amount of water is 5-10 times the amount of the total medicinal materials.

[0023] Preferably, the decoction is followed by filtration, and the filtrates are combined, concentrated, and dried to obtain the product.

[0024] The third object of the present invention is to provide a pharmaceutical preparation comprising the above composition and pharmaceutically acceptable excipients.

[0025] Another object of the present invention is to provide the use of the above composition in the preparation of drugs for preventing and treating cardiovascular diseases and / or cognitive impairment after cardiovascular diseases.

[0026] Preferably, the cardiovascular disease includes coronary heart disease, including one or more of chronic coronary syndrome or acute myocardial ischemia / myocardial infarction; and / or the drug can improve cognitive impairment in patients with coronary heart disease, as well as previous unstable angina and myocardial infarction.

[0027] The cardiovascular diseases include coronary heart disease.

[0028] Preferably, the drug can improve cardiac function and cardiac structure after acute myocardial ischemia injury, and / or reduce the area of ​​ischemic myocardial infarction, and / or alleviate myocardial cell damage and myocardial fibrosis, and / or alleviate damage to hippocampal neurons and ultrastructural changes, and / or improve learning and memory function and cognitive behavioral performance

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] (1) The red peony root in the formula can clear the blood vessels, dissipate blood stasis and relieve pain. It is cool in nature. When combined with Chuanxiong, which can move the blood and qi, dissipate blood stasis and relieve stagnation, the cold and warm properties are suitable, and the effect of promoting blood circulation and removing blood stasis is doubled. Alpinia oxyphylla can nourish the kidney, consolidate essence and reduce urination, warm the spleen and stop diarrhea, and improve complexion and prolong life. Lycium barbarum is neutral in nature and enters the liver and kidney meridians, nourishing the liver and kidney, improving essence and improving eyesight. Fenxinmu is bitter and astringent in taste and neutral in nature and enters the spleen and kidney meridians, promoting urination and clearing heat, strengthening the spleen and consolidating the kidney, and stopping nocturnal emission. It is used together with Alpinia oxyphylla and Lycium barbarum to enhance the effect of nourishing the kidney, producing essence, and strengthening the body. In addition, ginseng can protect the heart, improve intelligence, and regulate qi and blood. Lotus seed heart can clear the heart and relieve restlessness. Combined with red peony root, it can clear the heat in the blood and prevent blood stasis from turning into heat and toxicity. The whole formula has the effects of promoting blood circulation and removing blood stasis, detoxifying and clearing the heart, nourishing the kidney and replenishing deficiency, and improving intelligence and strengthening the body.

[0031] (2) The present invention uses SD rats, a rodent species that is easy to operate, reliable in source, and can be replicated on a large scale, to construct a rat model of acute myocardial ischemia-induced cognitive impairment by ligating the left anterior descending coronary artery. This operation technique is mature and reliable and can be used for drug screening and efficacy evaluation of this disease. The present invention successfully constructed a rat model of acute myocardial ischemia-induced cognitive impairment and screened out a traditional Chinese medicine compound with the effects of improving cardiac function and protecting cognition. This compound is based on the traditional Chinese medicine theory of "treating the heart and brain together" and the various components cooperate with each other to achieve excellent results. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 Ultrasound images of rats in the sham operation group.

[0033] Figure 2 Ultrasound images of rats in the model group.

[0034] Figure 3 This is the ultrasound image of rats in Example 1.

[0035] Figure 4 is the ejection fraction (LVEF) of rats’ cardiac ultrasound index; compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0036] Figure 5 is the short axis shortening rate (LVFS) of rat heart ultrasound index; compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0037] Figure 6 is the left ventricular end-diastolic diameter (LVIDd) of rats; compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0038] Figure 7 The left ventricular end-systolic diameter (LVIDs) of the rat heart ultrasound index is shown in Table 1. Compared with the blank group, #P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0039] Figure 8 This is a picture of TTC staining of rat heart.

[0040] Figure 9 The ischemic myocardial infarction area / heart area percentage of rats stained with TTC ischemic myocardial infarction area / heart area percentage (%). # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0041] Figure 10 HE staining and Masson staining images of myocardial tissues of rats in each group; A is HE staining, and B is Masson staining.

[0042] Figure 11 is the number of times the rats in each group crossed the platform in the water maze experiment.

[0043] Figure 12 is the distance traveled by each group of rats in the target quadrant.

[0044] Figure 13 is the time spent by rats in each group in the target quadrant.

[0045] Figure 14 The typical swimming paths of the rats in the navigation and spatial exploration experiments are shown in Figure 2. The red and blue squares represent the starting and ending points of the swimming movement, respectively, and the circle represents the location of the platform.

[0046] Figure 15 Pathological images of the CA1 region of the hippocampus tissue of rats in each group, where A is HE staining (×100) and B is Nissl staining (×100).

[0047] Figure 16 The synaptic ultrastructure of CA1 region of hippocampal tissue in rats of each group was observed under electron microscope (×20500).

[0048] The unclear parts in the above figures do not affect the understanding of the technical solution of the present invention by those skilled in the art. DETAILED DESCRIPTION

[0049] The present invention will be further described below with reference to specific embodiments.

[0050] Example 1

[0051] The present embodiment prescription is as follows:

[0052] 15 parts of Alpinia oxyphylla, 15 parts of wolfberry fruit, 15 parts of fenxinmu, 3 parts of lotus seed core, 10 parts of ginseng, 10 parts of chuanxiong, and 10 parts of red peony root.

[0053] The preparation method is:

[0054] (1) Weigh each component of the Chinese herbal medicine compound and mix well;

[0055] (2) Add 8 times the volume of water to the mixed Chinese medicinal materials and boil them for the first time for 1.5 hours. Filter and collect the medicinal liquid;

[0056] (3) Add 6 times the volume of water to the residue after the first extraction and boil it for a second time for 1 hour. Filter and collect the liquid.

[0057] (4) Mixing the two extracted medicinal solutions to obtain the aqueous extract of the Chinese herbal compound;

[0058] (5) The water extract is subjected to rotary evaporation to evaporate the water in the water extract and extract a more concentrated medicinal liquid in the form of a thick paste. The liquid is placed in a container and then dried and crushed into fine powder to obtain a dry paste powder. The powder is stored in a cool and dry place for future use.

[0059] Example 2

[0060] The present embodiment prescription is as follows:

[0061] 25 parts of Alpinia oxyphylla, 25 parts of wolfberry fruit, 25 parts of fenxinmu, 10 parts of lotus seed core, 15 parts of ginseng, 15 parts of chuanxiong, and 15 parts of red peony root.

[0062] The preparation method is:

[0063] (1) Weigh each component of the Chinese herbal medicine compound and mix well;

[0064] (2) Add 8 times the volume of water to the mixed Chinese medicinal materials and boil them for the first time for 1.5 hours. Filter and collect the medicinal liquid;

[0065] (3) Add 6 times the volume of water to the residue after the first extraction and boil it for a second time for 1 hour. Filter and collect the liquid.

[0066] (4) Mixing the two extracted medicinal solutions to obtain the aqueous extract of the Chinese herbal compound;

[0067] (5) The water extract is subjected to rotary evaporation to evaporate the water in the water extract and extract a more concentrated medicinal liquid in the form of a thick paste. The liquid is placed in a container and then dried and crushed into fine powder to obtain a dry paste powder. The powder is stored in a cool and dry place for future use.

[0068] Example 3

[0069] The present embodiment prescription is as follows:

[0070] 20 parts of Alpinia oxyphylla, 20 parts of wolfberry fruit, 20 parts of fenxinmu, 6 parts of lotus seed core, 5 parts of ginseng, 5 parts of chuanxiong, and 5 parts of red peony root.

[0071] The preparation method is:

[0072] (1) Weigh each component of the Chinese herbal medicine compound and mix well;

[0073] (2) Add 8 times the volume of water to the mixed Chinese medicinal materials and boil them for the first time for 1.5 hours. Filter and collect the medicinal liquid;

[0074] (3) Add 6 times the volume of water to the residue after the first extraction and boil it for a second time for 1 hour. Filter and collect the liquid.

[0075] (4) Mixing the two extracted medicinal solutions to obtain the aqueous extract of the Chinese herbal compound;

[0076] (5) The water extract is subjected to rotary evaporation to evaporate the water in the water extract and extract a more concentrated medicinal liquid in the form of a thick paste. The liquid is placed in a container and then dried and crushed into fine powder to obtain a dry paste powder. The powder is stored in a cool and dry place for future use.

[0077] Comparative Example 1

[0078] The difference from Example 1 is that the formula is different, specifically: 15 parts of Alpinia oxyphylla, 15 parts of Lycium barbarum, 15 parts of Rhizoma Dioscoreae, 3 parts of Radix Ophiopogonis, 10 parts of Ginseng, 10 parts of Rhizoma Chuanxiong, and 10 parts of Radix Paeoniae Rubra.

[0079] Comparative Example 2

[0080] The difference from Example 1 is that the formula is different, specifically: 15 parts of Alpinia oxyphylla, 15 parts of wolfberry, 15 parts of Psoralea corylifolia, 3 parts of lotus seed core, 10 parts of ginseng, 10 parts of safflower, and 10 parts of peach kernel.

[0081] The above parts are all parts by weight.

[0082] Effect of the Chinese herbal compound of the present invention on myocardial remodeling and cognitive function in rats with acute myocardial ischemia and cognitive impairment

[0083] Modeling and Grouping: An acute myocardial ischemic injury model was established in SD rats by surgical ligation of the left anterior descending coronary artery. A sham-operated group was treated with suture threading without ligation. Based on electrocardiogram (ECG) results and postoperative status, the rats were divided into the following groups: sham-operated group (blank), model group (model), and Example 1 group, with 18 rats in each group.

[0084] Administration and Dosage: Yields were calculated according to the rat-to-human dosage conversion method in "Laboratory Animals and Animal Experimental Techniques." The oral administration dose of the compositions of Examples 1-3 (the present invention's formulations) and Comparative Examples 1-2 was 8.19 g / kg / day [preparation of the traditional Chinese medicine compound dry paste powder is the same as described above]. The sham-operated and model groups were administered an equal volume of purified water by oral gavage. Rats in each group began drug administration the day after modeling. Rats were weighed weekly, and the dosage was adjusted based on body weight fluctuations. Drug administration continued for 6 weeks.

[0085] Experimental testing: Echocardiography was used to evaluate cardiac structure and function, and Morris water maze was used to observe cognitive and behavioral changes. Myocardial tissue samples were collected for HE and Masson pathological staining, and TTC staining was used to detect ischemic myocardial infarction area. HE and Nissl staining were used to observe hippocampal pathological changes, and transmission electron microscopy was used to observe synaptic ultrastructure of brain tissue.

[0086] Experimental results:

[0087] (1) Echocardiography Figure 1-7 : Compared with the blank group, the LVEF and LVFS of the rats in the model group were significantly decreased ( P <0.01), LVIDd and LVIDs increased significantly ( P <0.01), it can be seen that the ventricular cavity of the model group was dilated and the cardiac function was weakened; compared with the model group, the LVEF and LVFS values ​​of the rats in Example 1 group were significantly increased ( P <0.01), LVIDd and LVIDs values ​​were significantly reduced ( P <0.01).

[0088] (2) The gross appearance of the heart and the area of ​​ischemic myocardial infarction Figure 8-9 The heart surface of the blank group was smooth, the myocardium was red, the shape was elastic, and no discoloration was observed. In the surgical ligation groups, the left ventricular infarction area turned white, the myocardium was dark, the ventricular wall became thinner and collapsed, and the ventricular cavity enlarged. This was most obvious in the model group. TTC staining showed a significant increase in the infarction area ( P <0.01); compared with the model group, the changes in heart morphology, myocardial color and ventricular wall in the intervention group of Example 1 were alleviated, and the infarct area was reduced.

[0089] (3) The results of myocardial tissue pathology are shown in Figure 10 :

[0090] HE staining: The myocardial cells of the rats in the blank group were arranged neatly and intact, the myocardial tissue fibers were dense, the transverse striations were clear, and no inflammatory cell infiltration was observed; the myocardial cells of the rats in the model group were arranged disorderly, with extensive necrosis, thickening and rupture of myocardial fibers, and a large number of inflammatory cell infiltrations were observed in the interstitium; compared with the model group, the myocardial damage in the intervention group of Example 1 was milder, and the inflammatory cell infiltration was reduced.

[0091] Masson staining: in the blank group, myocardial cells were arranged neatly, and a small amount of collagen fiber deposition was found in the myocardial interstitial space; in the model group, a large amount of blue staining and collagen fiber deposition appeared in the edge area of ​​myocardial infarction, and myocardial cells were arranged disorderly; compared with the model group, the blue staining area in the intervention group of Example 1 was significantly reduced.

[0092] (4) Cognitive behavioral science:

[0093] Morris water maze test results are shown in Figure 11-14 : Compared with the blank group, the incubation period of rats in the model group was significantly prolonged ( P <0.01), the number of times crossing the platform, the distance and time spent in the target quadrant were significantly reduced ( P <0.01); Compared with the model group, the incubation period of the intervention group of Example 1 was shortened on the third and fifth days ( P <0.05), the number of times crossing the platform increased (P<0.05), and the activity distance and time in the quadrant where the original platform was located increased significantly.

[0094] Table 1 Escape latency of rats in each group (x ± s)

[0095]

[0096] Note: Compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05, ** P <0.01.

[0097] (5) The results of brain tissue pathology are shown in Figure 15 :

[0098] HE staining: The hippocampal tissue structure of the rats in the blank group was normal, the pyramidal cells in the CA1 region were relatively regular circles or ovals, the granule cells and neurons were neatly arranged, tightly connected, plump in morphology, and with clear nucleoli; the above cells and neurons in the CA1 region of the hippocampal tissue of the rats in the model group were relatively disordered, with reduced numbers, loose gaps, unclear layers, blurred cell membranes and nucleoli, and some cell nuclei were deformed and condensed; compared with the model group, the pathological changes in the hippocampus of the rats in the intervention group according to Example 1 were milder, the cell structure was clearer and more complete, and the arrangement was neater and tighter.

[0099] Nissl staining: The cells in the CA1 region of the hippocampus of the blank group rats were arranged more neatly, the number of neurons distributed in layers was larger, the outlines of the nerve cells were clear and complete, and the number of Nissl bodies in the cytoplasm was relatively abundant; the neurons in the hippocampus of the model group rats were arranged irregularly, the number of Nissl bodies was significantly reduced or even disappeared, the staining was significantly lighter, and nuclear condensation was present; compared with the model group, the neurons in the Example 1 group were arranged more regularly, the cell outlines were clearer, the Nissl bodies were reduced to a certain extent, and the cytoplasm staining was darker.

[0100] (6) Transmission electron microscopy results of hippocampal synaptic ultrastructure are shown in Figure 16 : The synaptic structure of the rats in the blank group was clear, the distance and morphology of the synaptic cleft were normal, the contours of the presynaptic and postsynaptic membranes were complete, and more synaptic vesicles were visible in the larger presynaptic swell; the postsynaptic density zone in the CA1 region of the hippocampus of the rats in the model group was smaller, the morphology was blurred, and the synaptic vesicles were scattered; compared with the model group, the synaptic structure of the CA1 region of the hippocampus of the rats in the Example 1 group was clearer, the presynaptic membrane morphology was normal, and the thickness of the postsynaptic density zone was relatively normal and uniform.

[0101] Conclusion: The prescription of the present invention can improve the cardiac function and cardiac structure of rats after acute myocardial ischemia injury, reduce the area of ​​ischemic myocardial infarction, alleviate myocardial cell damage and myocardial fibrosis, relieve the damage of hippocampal neurons and ultrastructural changes, and improve learning and memory function and cognitive behavioral performance.

Claims

1. A Chinese medicine composition for improving cognitive impairment in coronary heart disease, characterized in that: The raw materials of the composition are prepared from the following components: 15-25 parts of Alpinia oxyphylla seeds, 15-25 parts of wolfberry fruits, 15-25 parts of Psoralea corylifolia, 3-10 parts of lotus seed core, 5-15 parts of ginseng, 5-15 parts of Chuanxiong and 5-15 parts of red peony root.

2. The composition according to claim 1, characterized in that The raw materials of the composition are prepared from the following components by weight: 15-20 parts of Alpinia oxyphylla, 15-20 parts of wolfberry, 15-20 parts of Psoralea corylifolia, 3-6 parts of lotus seed core, 10-15 parts of ginseng, 10-15 parts of Chuanxiong and 10-15 parts of red peony root.

3. A method for preparing the composition according to any one of claims 1 to 2, characterized in that: The preparation comprises mixing Alpinia oxyphylla, wolfberry, Fenxinmu, lotus seed core, ginseng, Chuanxiong and red peony root, adding water and boiling.

4. The preparation method according to claim 3, characterized in that The number of decoctions is 1-3 times, and the decoction time for each time is 0.5-1.5; And / or, the amount of water used is 5-10 times the total amount of medicinal materials.

5. The preparation method according to claim 3, characterized in that After the decoction, the product is filtered, the filtrates are combined, concentrated, and dried to obtain the product.

6. A pharmaceutical preparation, characterized in that The preparation comprises the traditional Chinese medicine composition according to any one of claims 1 to 2 and pharmaceutically acceptable excipients.

7. Use of the traditional Chinese medicine composition according to any one of claims 1 to 2 in the preparation of a drug for preventing and treating cardiovascular disease and / or cognitive impairment after cardiovascular disease, characterized in that: The cardiovascular disease is one or both of coronary heart disease and acute myocardial ischemia injury.

Images